{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:23:33Z","timestamp":1787376213965,"version":"build-2736575974"},"reference-count":94,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is frequently diagnosed at advanced stages, thereby limiting curative treatment options. Although interventions with curative intent, such as liver resection and ablation, are available, recurrence rates exceed 70%. Recent developments in HCC management have shifted the focus from conventional surgery and targeted therapies to immunotherapy. This review synthesizes current evidence on immunotherapy for curative purposes in HCC, including both neoadjuvant and adjuvant strategies. It evaluates completed and ongoing clinical trials of immune checkpoint inhibitors (ICIs), administered as monotherapy or in combination with anti-angiogenic agents or dual-checkpoint blockade. ICIs may transform the initial treatment paradigm for advanced HCC, although their applications remain in the investigational stage. Preliminary results from the IMbrave050 trial suggested that adjuvant immunotherapy following radical liver resection improves recurrence-free survival (RFS) in high-risk patients. However, the initially promising outcomes of the combination of atezolizumab and bevacizumab compared with active surveillance were not sustained in the median follow-up, and long-term survival results are awaited. Although several studies have demonstrated encouraging preliminary results, a clear survival benefit has not yet been established. Further studies are necessary to establish definitive conclusions. Immunotherapy has a pathophysiological basis and preliminary evidence to redefine HCC management across disease stages; its integration into pre- and post-operative strategies may increase resectability, reduce recurrence, and improve survival. Ongoing trials are expected to clarify its exact role.<\/jats:p>","DOI":"10.3390\/curroncol33080492","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:05:19Z","timestamp":1787241919000},"page":"492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Role of Immunotherapy in the Treatment with Curative Purpose of Early, Intermediate and Advanced Stage Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"33","author":[{"given":"Anastasia D.","family":"Karampa","sequence":"first","affiliation":[{"name":"HPB Unit, Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Goussia","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8448-3131","authenticated-orcid":false,"given":"Evangelos G.","family":"Baltagiannis","sequence":"additional","affiliation":[{"name":"HPB Unit, Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1048-0960","authenticated-orcid":false,"given":"Nikolaos-Andreas T.","family":"Anastasopoulos","sequence":"additional","affiliation":[{"name":"HPB Unit, Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios K.","family":"Christodoulou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios K.","family":"Glantzounis","sequence":"additional","affiliation":[{"name":"HPB Unit, Department of Surgery, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology; implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Georges","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Polpichai, N., Saowapa, S., Danpanichkul, P., Chan, S.-Y., Sierra, L., Blagoie, J., Rattananukrom, C., Sripongpun, P., and Kaewdech, A. (2024). Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226770"},{"key":"ref_4","first-page":"453","article-title":"Recent advances in the surgical management of hepatocellular carcinoma","volume":"34","author":"Glantzounis","year":"2021","journal-title":"Ann. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Morishita, A., Oura, K., Tai, H., Yano, R., Nakahara, M., Tadokoro, T., Fujita, K., Mimura, S., Tani, J., and Tatsuta, M. (2026). Advances in the Therapeutic Landscape of Hepatocellular Carcinoma: Current Strategies and Future Perspectives. Cancers, 18.","DOI":"10.3390\/cancers18040609"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Choi, H.W., Kim, J.S., Lee, T.Y., and Yoon, Y.C. (2024). Update on Resection Strategies for Hepatocellular Carcinoma: A Narrative Review. Cancers, 16.","DOI":"10.3390\/cancers16234093"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Glantzounis, G.K., Korkolis, D., Sotiropoulos, G.C., Tzimas, G., Karampa, A., Paliouras, A., Asimakopoulos, A.-G., Davakis, S., Papalampros, A., and Moris, D. (2022). Individualized Approach in the Surgical Management of Hepatocellular Carcinoma: Results from a Greek Multicentre Study. Cancers, 14.","DOI":"10.3390\/cancers14184387"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fite, E.L., Sekar, N., Venancius, J.S., and Makary, M.S. (2026). Hepatocellular Carcinoma Bridging and Downstaging: Advances in Locoregional Therapy. Biomedicines, 14.","DOI":"10.3390\/biomedicines14040877"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/OP.24.00189","article-title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights","volume":"20","author":"Rose","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_11","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s12072-024-10732-z","article-title":"APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024","volume":"8","author":"Lau","year":"2024","journal-title":"Hepatol. Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41571-026-01160-z","article-title":"Trial design and end points in hepatocellular carcinoma: An EASL\u2013AASLD\u2013ILCA consensus statement","volume":"23","author":"Llovet","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.17998\/jlc.2025.02.03","article-title":"A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017\u20132024","volume":"25","author":"Shin","year":"2025","journal-title":"J. Liver Cancer"},{"key":"ref_16","first-page":"223","article-title":"Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update","volume":"14","author":"Bi","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.21037\/hbsn-20-865","article-title":"Radiological simultaneous portohepatic vein embolization (RASPE) and major hepatectomy with hepatocellular carcinoma (HCC)","volume":"10","author":"Glantzounis","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1245\/s10434-025-17607-z","article-title":"Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu","volume":"32","author":"Wong","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.amsu.2021.103043","article-title":"Metronomic chemotherapy with cyclophosphamide for the treatment of advanced hepatocellular cancer: A case report","volume":"72","author":"Peristeri","year":"2021","journal-title":"Ann. Med. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): An open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_23","unstructured":"Cindy Hochstetler, N., Schonfeld, R., Benson, A.B., Abrams, T., Anaya, D.A., and Anders, R. (2025). NCCN Guidelines Version 1.2025 Hepatocellular Carcinoma. NCCN Guidelines Index, National Comprehensive Cancer Network."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"CT003","DOI":"10.1158\/1538-7445.AM2021-CT003","article-title":"Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","volume":"81","author":"Forde","year":"2021","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2019.08.014","article-title":"The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications","volume":"72","author":"Hou","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_28","first-page":"2019","article-title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial","volume":"20","author":"Marron","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3892\/ol.2025.15204","article-title":"Neoadjuvant immunotherapy for resectable primary liver cancer (Review)","volume":"30","author":"Deng","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tian, C., Yu, Y., Wang, Y., Yang, L., Tang, Y., Yu, C., Feng, G., Zheng, D., and Wang, X. (2024). Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: A meta-analysis and systematic review. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1352873"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant\u2013Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2023.2677","article-title":"Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review","volume":"10","author":"Cappuyns","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"4","author":"Llovet","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1172\/JCI134402","article-title":"Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy","volume":"130","author":"Li","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chai, Y., Xu, T., Chen, X., Chen, B., Du, X., and Zhang, Z. (2025). Immunotherapy targeting liver cancer tumor-initiating cells: Challenges, mechanisms, and emerging therapeutic horizons. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1621243"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell\u2013CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s44342-024-00034-z","article-title":"Comprehensive Analysis of TCR and BCR Repertoires: Insights into Methodologies, Challenges, and Applications","volume":"23","author":"Seo","year":"2025","journal-title":"Genom. Inform."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S1842","DOI":"10.1016\/j.annonc.2025.10.095","article-title":"LBA4 WES-powered MRD navigation for adjuvant therapy in hepatocellular carcinoma","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity","volume":"9","author":"Ho","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): A randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2025.43.4_suppl.582","article-title":"IMMULAB: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC)\u2014The IKF-IMMULAB trial","volume":"43","author":"Vogel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2025.43.4_suppl.609","article-title":"Safety and efficacy of combining PD-L1 and CTLA-4 blockade with transarterial chemoembolization in intermediate-stage hepatocellular carcinoma: A phase II study","volume":"43","author":"Kim","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Shi, Y.-H., Ji, Y., Liu, W.-R., and Pang, Y.-R. (2021, January 10\u201315). Abstract 486: A phase Ib\/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, Philadelphia, PA, USA.","DOI":"10.1158\/1538-7445.AM2021-486"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e16292","DOI":"10.1200\/JCO.2025.43.16_suppl.e16292","article-title":"Tislelizumab as monotherapy or in sequential combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma: A prospective, phase II clinical study","volume":"43","author":"Han","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.2023.41.16_suppl.4120","article-title":"Camrelizumab in combination with apatinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: A prospective, single-arm, phase 2 study","volume":"41","author":"Cui","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e16283","DOI":"10.1200\/JCO.2026.44.16_suppl.e16283","article-title":"Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A\/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial","volume":"44","author":"Peng","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Chen, K., Luo, C.-P., Ge, D.-X., Wang, K.-L., Luo, Q., Li, Y.-Z., You, X.-M., Xiang, B.-D., Li, L.-Q., and Ma, L. (2022). Case report: Conversion therapy to permit resection of initially unresectable hepatocellular carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.946693"},{"key":"ref_52","first-page":"1","article-title":"Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma","volume":"14","author":"Masatoshi","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e256931","DOI":"10.1136\/bcr-2023-256931","article-title":"Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy","volume":"16","author":"Bidarmaghz","year":"2023","journal-title":"BMJ Case Rep."},{"key":"ref_54","first-page":"1","article-title":"Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: A case report","volume":"16","author":"Liang","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e013516","DOI":"10.1136\/jitc-2025-013516","article-title":"Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma","volume":"12","author":"Zhang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial","volume":"40210415","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","article-title":"Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma","volume":"84","author":"Yopp","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.gastro.2015.02.055","article-title":"Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma","volume":"148","author":"Lee","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jgh.70318","article-title":"Immune Checkpoint Inhibitor\u2013Based Adjuvant Treatment Versus Surveillance in Curatively Treated Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"41","author":"Akkus","year":"2026","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.jhep.2026.02.011","article-title":"Adjuvant immunotherapy for hepatocellular carcinoma. Precision selection of the optimal target population as the core strategy","volume":"85","author":"Su","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-026-04301-6","article-title":"Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Real-world data and 9-year extended follow-up of a randomized controlled trial","volume":"75","author":"Shin","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"Geissler","year":"2016","journal-title":"Transplantation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","article-title":"Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: A randomized, controlled, phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e16238","DOI":"10.1200\/JCO.2024.42.16_suppl.e16238","article-title":"Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study","volume":"42","author":"Pan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/JCO.2026.44.2_suppl.477","article-title":"Adjuvant pembrolizumab for participants with hepatocellular carcinoma and complete radiologic response after surgical resection or local ablation: The phase 3 keynote-937 study","volume":"44","author":"Chan","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1177\/0003134820942165","article-title":"HCC Liver transplantation wait list dropout rates before and after the mandated 6-month wait time","volume":"86","author":"Sokolich","year":"2020","journal-title":"Am. Surg."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2025.03.001","article-title":"Short-term prognosis of recipients with pretransplant exposure to immune checkpoint inhibitors after liver transplantation for hepatocellular carcinoma: A retrospective cohort study","volume":"9","author":"Pang","year":"2025","journal-title":"Liver Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1097\/JS9.0000000000001813","article-title":"Pembrolizumab in combination with LEnvatinib in participants with hepatocellular carcinoma before liver transplant as Neoadjuvant TherapY\u2014PLENTY pilot study","volume":"110","author":"Lv","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jhep.2026.02.019","article-title":"Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)","volume":"85","author":"Bhoori","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"28.09","DOI":"10.4049\/jimmunol.206.Supp.28.09","article-title":"Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma (Dulect2020-1)","volume":"206","author":"Feng","year":"2021","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e0158","DOI":"10.1097\/CLD.0000000000000158","article-title":"Approach to immunotherapy for HCC in the liver transplant population","volume":"23","author":"Block","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"101363","DOI":"10.1016\/j.jceh.2024.101363","article-title":"Rejection in Liver Transplantation Recipients","volume":"14","author":"Maddur","year":"2024","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2016). Electronic address eee EASL clinical practice guidelines: Liver transplantation. J. Hepatol., 64, 433\u2013485.","DOI":"10.1016\/j.jhep.2015.10.006"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2021.07.027","article-title":"Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective","volume":"75","author":"Lee","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.jhep.2024.07.025","article-title":"Strategic timing and patient selection for ICIs prior to liver transplantation for HCC","volume":"82","author":"Hao","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Wassmer, C.-H., El Hajji, S., Papazarkadas, X., Compagnon, P., Tabrizian, P., and Lacotte, S. (2023). Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers, 15.","DOI":"10.3390\/cancers15184574"},{"key":"ref_79","first-page":"107","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis","volume":"82","author":"Yeo","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/ITT.S528709","article-title":"Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review","volume":"14","author":"Akabane","year":"2025","journal-title":"ImmunoTargets Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.ajt.2026.02.010","article-title":"Immune checkpoint inhibitors after liver transplantation: The role of immunosuppressive management","volume":"26","author":"Antonini","year":"2026","journal-title":"Am. J. Transplant."},{"key":"ref_82","first-page":"251","article-title":"Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma","volume":"29","author":"Zhu","year":"2018","journal-title":"Sage J."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Abudoureyimu, M., Lai, Y., Tian, C., Wang, T., Wang, R., and Chu, X. (2019). Oncolytic Adenovirus\u2014A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01182"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: A global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14737140.2025.2461631","article-title":"Advancements in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Ascari","year":"2025","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bouguerra, R., El Hajji, S., Wassmer, C.-H., Bakaric, A., Slits, F., Moeckli, B., Rubbia-Brandt, L., Lacotte, S., and Toso, C. (2025). Hepatectomy alters adjuvant anti-PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy. Hepatology, ahead of print.","DOI":"10.1097\/HEP.0000000000001575"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/HEP.0000000000001433","article-title":"Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy","volume":"83","author":"Su","year":"2026","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5306\/wjco.v13.i6.448","article-title":"Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances","volume":"3","author":"Rallis","year":"2022","journal-title":"World J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40164-025-00636-5","article-title":"Targeting immune checkpoints in hepatocellular carcinoma therapy: Toward combination strategies with curative potential","volume":"14","author":"Tong","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_90","first-page":"4616","article-title":"Transplant Versus Non-Transplant Hepatocellular Carcinoma Patient Characteristics And Survival","volume":"10","author":"Carr","year":"2025","journal-title":"World J. Med. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e70094","DOI":"10.1002\/cam4.70094","article-title":"Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis","volume":"13","author":"Wen","year":"2024","journal-title":"Cancer Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Gonzalez-Larreategui, I., Valdes-Bango Martin, M., Casacuberta-Serra, S., and Soucek, L. (2026). MYC at the tumor\u2013immune interface: Mechanisms of immune escape and immunotherapy resistance. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1738440"},{"key":"ref_93","first-page":"1","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Bloom, M., Podder, S., Dang, H., and Li, D. (2025). Advances in Immunotherapy in Hepatocellular Carcinoma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051936"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:24:30Z","timestamp":1787372670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/8\/492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":94,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["curroncol33080492"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33080492","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}